Skip to main content
MarketsReportedMediumDeveloping
5.0

J&J in talks to acquire eye-disease biotech Ollin Biosciences for up to $3.4bn

Johnson & Johnson is reportedly in talks to acquire Ollin Biosciences, an eye-disease biotech, for up to $3.4 billion. The deal would be the latest in a wave of biotech M&A, reflecting continued consolidation in the sector. Financial terms and final agreement remain unconfirmed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

Financial Timesabout 8 hours agoUSengCredibility 50%View source

Score Breakdown

Mosaic Score5.0
Model confidence0.5
Significance0.5
Source credibility0.5

Intelligence Tags

Entities

United Statescountry
Source

Related signals

8 found